StockStory.org on MSN1h
Abbott Laboratories (NYSE:ABT) Posts Q4 Sales In Line With Estimates
Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q4 CY2024, with sales up 7.2% year on year to $10.97 ...
Abbott Laboratories: Strong Q4 Results And Bullish Outlook
Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...
Jim Cramer Says Abbott Laboratories (ABT) ‘Was The Market Leader Yesterday. That’s New’
We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...
Abbott Laboratories (ABT): How Hot Money Found Its Way Into This Healthcare Giant
We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks.
The Art of Valuation: Discovering Abbott Laboratories's Intrinsic Value
In this article, we will take a look into Abbott Laboratories's (NYSE:ABT) DCF analysis, a reliable and data-driven approach ...
Abbott Laboratories stock underperforms Monday when compared to competitors despite daily gains
This was the stock's fifth consecutive day of gains.
Abbott Laboratories stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Barclays Remains a Buy on Abbott Laboratories (ABT)
In a report released today, Matt Miksic from Barclays maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price ...
Argus Research Sticks to Their Buy Rating for Abbott Laboratories (ABT)
In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The ...
Jim Cramer Recommends Abbott Laboratories (ABT) – ‘Their Legal Stuff Is Largely Behind Them’
Jim Cramer in a latest program on CNBC discussed the reasons behind the recent market declines after the ISM Services Index ...
bovnews6d
What’s Driving Abbott Laboratories (ABT) Stock’s 9.45% Surge Over the Past Month?
Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had ...
Motley Fool: A health care dynamo
Abbott Laboratories (NYSE: ABT) is a well-diversified health care company, with four distinct units: medical devices, ...